Skin Cancer
In 2026, the use of Full Extract Cannabis Oil (FECO) for skin cancer is a topic of significant scientific interest, particularly regarding Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), and Melanoma.
The historical foundation for this treatment comes from the anecdotal "Rick Simpson" protocol, which involves direct topical application. Modern research has since begun to explore the mechanisms behind why this may be effective.
1. The Treatment Protocol: Topical vs. Oral
When treating skin cancer, FECO is typically used in a two-pronged approach to target the cancer both locally and systemically.
A. Topical Application (Targeted)
The skin is "jam-packed" with CB2 receptors, which regulate cell growth and inflammation.
Direct Application: A small amount of FECO (often the size of a pinhead) is applied directly onto the lesion.
Occlusion: The area is covered with a waterproof bandage. This is crucial as it prevents the oil from rubbing off and creates a "greenhouse effect," increasing the absorption of cannabinoids into the deeper layers of the dermis.
Frequency: Most protocols suggest reapplying every 24 to 48 hours, gently cleaning the area between applications.
B. Oral Ingestion (Systemic)
Ingesting FECO helps manage the body’s overall internal environment and may help prevent metastasis (spreading).
The "90-Day Protocol": Traditional anecdotal protocols suggest a goal of consuming 60 grams over 90 days, starting with a dose the size of half a grain of rice and doubling it every few days as tolerance builds.
Caution: This high dose is highly psychoactive and should only be done under the supervision of a cannabis-literate health professional.
2. Mechanisms of Action
Current studies (such as those from Charles Darwin University in 2024–2025) have identified specific ways FECO interacts with skin cancer:
Apoptosis: Cannabinoids bind to receptors on melanoma and BCC cells, signaling the cell to initiate "programmed cell death.
Cell Cycle Arrest: FECO can "freeze" the growth of cancer cells at the G1/S phase, preventing them from dividing into new cells.
Anti-Angiogenesis: It helps block the tumor’s ability to grow new blood vessels, essentially starving the lesion of its nutrient supply.
3. Comparison by Skin Cancer Type
| Type | Potential Effectiveness | Notable Research |
|---|---|---|
| Basal Cell (BCC) | High (Anecdotal) | Often the most responsive to topical FECO in patient reports. |
| Squamous Cell (SCC) | High | Research shows CBD + CBC combinations are particularly cytotoxic to SCC cells. |
| Melanoma | High | Highly aggressive; 2024 research (PHEC-66) shows promise in "killing" cells, but medical surgery is still the gold standard. |
4. Safety and 2026 Medical Reality
The "Cure" Debate: While FECO has shown the ability to kill cancer cells in lab settings, there is no definitive clinical evidence that it can reliably cure skin cancer in humans as a standalone treatment.
Warning: Melanoma can spread rapidly to the lungs and brain. FECO should be used as a complementary therapy alongside a dermatologist's care, not as a replacement for surgical excision.
